The INSPIRA ART100 medical device is intended for pulmonary and cardiac support. Credit: Chinnapong/Shutterstock.com.

Inspira Technologies has concluded a Usability Study for its INSPIRA ART100 blood circulation medical device in Boston, Massachusetts, US.

The study involved US healthcare professionals assessing and examining the device in a setting that has been designed to consider the human aspects of the intended users, uses and use environments.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Inspira Technologies CEO Dagi Ben Noon said: “We are advancing with the INSPIRA ART100. We plan to take a position in disrupting the medical device industry with our high-grade technology.”

The extracorporeal blood circulation device is intended for pulmonary and cardiac support.

It constantly enriches the blood with oxygen while eliminating carbon dioxide.

See Also:

The device can be used in several extracorporeal treatments in the intensive care unit (ICU) and during heart surgery.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

INSPIRA ART100 is expected to be the first device that can be integrated with the company’s non-invasive HYLA blood sensor technology, which is intended to carry out continuous blood measurements in real time.

It features a large touchscreen and colourful graphical representation to enhance the visibility, scope and functionality of data presented to the medical staff.

The company plans to submit the INSPIRA ART100 device to the US Food and Drug Administration to obtain approval, in the latter half of this year.

In May this year, the company announced the development of a new augmented respiration technology, dubbed the VORTX Blood Oxygenator, to imitate lung function.

Inspira is focused on the development of medical technologies and products for the prevention of mechanical ventilation.